About palisade bio - PALI
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies for inflammatory bowel diseases. Its programs include PALI-2108 and LB1148. The company was founded on September 6, 2011 and is headquartered in Denver, CO.
PALI At a Glance
Palisade Bio, Inc.
4600 South Syracuse Street
Denver, Colorado 80237
| Phone | 1-858-704-4900 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -16,781,000.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PALI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.896 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.138 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.029 |
PALI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,198,642.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PALI Liquidity
| Current Ratio | 28.952 |
| Quick Ratio | 28.952 |
| Cash Ratio | 28.772 |
PALI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -23.111 |
| Return on Equity | -24.521 |
| Return on Total Capital | -12.963 |
| Return on Invested Capital | -24.521 |
PALI Capital Structure
| Total Debt to Total Equity | 0.055 |
| Total Debt to Total Capital | 0.055 |
| Total Debt to Total Assets | 0.053 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |